Author response to Marrs et al., Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial: a critical appraisal

Affiliations

¹ Department of Paediatric Allergy, Guy's and St Thomas' Hospitals NHS Foundation Trust, Westminster Bridge Road, London, U.K.
² Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Box 157, Cambridge, CB2 0QQ, U.K.

Comment

K Anagnostou et al. Br J Dermatol. 2015 Nov.

. 2015 Nov;173(5):1129-30.

doi: 10.1111/bjd.14160.

¹ Department of Paediatric Allergy, Guy's and St Thomas' Hospitals NHS Foundation Trust, Westminster Bridge Road, London, U.K.
² Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Box 157, Cambridge, CB2 0QQ, U.K.

No abstract available

Comment on

Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, Palmer C, Deighton J, Ewan P, Clark A. Anagnostou K, et al. Lancet. 2014 Apr 12;383(9925):1297-1304. doi: 10.1016/S0140-6736(13)62301-6. Epub 2014 Jan 30. Lancet. 2014. PMID: 24485709 Free PMC article. Clinical Trial.
Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial: a critical appraisal.
Marrs T, Flohr C, Perkin MR. Marrs T, et al. Br J Dermatol. 2015 Nov;173(5):1125-9. doi: 10.1111/bjd.14161. Br J Dermatol. 2015. PMID: 26769642